https://www.selleckchem.com/products/azd9291.html
A post hoc analysis to investigate the association between 1-year changes in albuminuria and subsequent risk of cardiovascular and renal events. LEADER was a randomized trial of liraglutide up to 1.8 mg/day versus placebo added to standard care for 3.5-5 years in 9,340 participants with type 2 diabetes and high cardiovascular risk. We calculated change in urinary albumin-to-creatinine ratio (UACR) from baseline to 1 year in participants with 30% reduction ( = 2,928), 30-0% reduction ( = 1,218), or any increase in UACR ( = 4,124), ir
Like
Comment
Share
